Free Trial

Enliven Therapeutics (ELVN) Earnings Date, Estimates & Call Transcripts

Enliven Therapeutics logo
$20.51 +0.66 (+3.32%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$20.50 -0.02 (-0.07%)
As of 08:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics Earnings Summary

Upcoming
Earnings Date
May. 13Before Market OpensEstimated
Consensus EPS
(Mar. 13)
-$0.53
Actual EPS
(Mar. 13)
-$0.46 Beat By $0.07
Actual Revenue
(Mar. 13)
$0.03M

Enliven Therapeutics issued Q4 2024 earnings on March 13, 2025, reporting an EPS of -$0.46, which beat the consensus estimate of -$0.53 by $0.07. Quarterly revenue was reported to be $0.03 million. With a trailing EPS of -$1.89, Enliven Therapeutics' earnings are expected to decrease next year, from ($1.95) to ($2.35) per share.

Q4 2024 Earnings Resources

ELVN Upcoming Earnings

Enliven Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Friday, May 9, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Get Enliven Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

ELVN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Enliven Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20251-$0.52-$0.52-$0.52
Q2 20251-$0.55-$0.55-$0.55
Q3 20251-$0.58-$0.58-$0.58
Q4 20251-$0.60-$0.60-$0.60

Enliven Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/13/2025
(Estimated)
--------
3/13/2025Q4 2024-$0.53-$0.46+$0.07-$0.46-$0.03M
8/13/2024--$0.58-$0.41+$0.17-$0.41--
5/14/2024Q1 2024-$0.58-$0.54+$0.04-$0.54--
3/14/2024Q4 2023-$0.56-$0.47+$0.09-$0.47--
11/9/2023Q3 2023-$0.49-$0.51 -$0.02-$0.51--
8/10/2023Q2 2023-$0.40-$0.41 -$0.01-$0.41--
5/11/2023Q1 2023-$0.67-$0.80 -$0.13-$0.80--

Enliven Therapeutics Earnings - Frequently Asked Questions

Enliven Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based off last year's report dates. Learn more on ELVN's earnings history.

In the previous quarter, Enliven Therapeutics (NASDAQ:ELVN) reported ($0.46) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.53) by $0.07. Learn more on analysts' earnings estimate vs. ELVN's actual earnings.

Enliven Therapeutics (NASDAQ:ELVN) has a recorded net income of -$71.58 million. ELVN has generated -$1.89 earnings per share over the last four quarters.

Enliven Therapeutics's earnings are expected to decrease from ($1.95) per share to ($2.35) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:ELVN) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners